BridgeMD
New treatment option for Cataract
Official title Comparison of Outcomes With Multifocal Intraocular Lenses
ClinicalTrials.gov ID: NCT02678962
What this study is testing
- What it's testing
- The purpose of this study is to compare and evaluate the clinical outcomes of 6 kinds of Multifocal Intraocular Lenses: SN6AD1, SBL-3, LS-313 MF30, AT LISA tri 839 MP, ART, LS-313 MF30T.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 80
You may be able to join if
- Age from 40 to 80 years old, either gender;
- Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation;
- Willing to undergo second eye surgery within 7 days after first eye surgery;
- The potential postoperative visual acuity of 20/40 or better in both eyes;
- Preoperative measurement of corneal astigmatism indicate the people are suitable for multifocal intraocular lenses implantation;
You likely can't join if
- Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;
- Preexisting systemic diseases or conditions that may confound the results of the study;
- Previous ocular surgery history or ocular trauma that may confound the results of the study;
- Require combined surgery that may confound the results of the study;
- Previous participation in other clinical trial within 30 days of this study start;
- Systemic or ocular medications that may confound the outcome of the intervention
See the full eligibility criteria
- Age from 40 to 80 years old, either gender;
- Patients with bilateral age related cataracts, require bilateral cataract phacoemulsification combined Intraocular Lens implantation;
- Willing to undergo second eye surgery within 7 days after first eye surgery;
- The potential postoperative visual acuity of 20/40 or better in both eyes;
- Preoperative measurement of corneal astigmatism indicate the people are suitable for multifocal intraocular lenses implantation;
- Capability to understand the informed consent and willing and able to attend study
- Preexisting ocular diseases or conditions other than age related cataracts, have contraindications for cataract surgery;
- Preexisting systemic diseases or conditions that may confound the results of the study;
- Previous ocular surgery history or ocular trauma that may confound the results of the study;
- Require combined surgery that may confound the results of the study;
- Previous participation in other clinical trial within 30 days of this study start;
- Systemic or ocular medications that may confound the outcome of the intervention
- Pregnant, lactating, or planning to become pregnant during the course of the trial;
The study team makes the final eligibility decision.
Where it's taking place
- Wenzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wenzhou, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.